Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017136486) ANTIBODY-DRUG SYNERGISM TECHNOLOGY FOR TREATING DISEASES
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/136486 International Application No.: PCT/US2017/016107
Publication Date: 10.08.2017 International Filing Date: 02.02.2017
IPC:
C07K 16/00 (2006.01) ,A61K 47/50 (2017.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
[IPC code unknown for A61K 47/50]
Applicants:
NI, Jinsong [US/US]; US
YANG, Rong [US/US]; US
Inventors:
NI, Jinsong; US
YANG, Rong; US
Agent:
SHAN, Feng; US
Priority Data:
62/291,36104.02.2016US
Title (EN) ANTIBODY-DRUG SYNERGISM TECHNOLOGY FOR TREATING DISEASES
(FR) TECHNOLOGIE DE SYNERGIE ANTICORPS-MÉDICAMENT PERMETTANT LE TRAITEMENT DE MALADIES
Abstract:
(EN) A method of producing synergistic and enhanced efficacy in treating a disease in a subject includes providing an antibody, the antibody being a classic antibody or a modified biologic molecule that blocks a first target in the subject; providing a drug, the drug being a small molecule agent that blocks the first target or a second target in the subject; connecting the antibody and the drug with a linker to form an Antibody-Drug Synergism (ADS) compound; and treating the disease with the ADS compound. The linker is hydrolyzed in the subject over a certain time so that both the antibody and the drug exert their functions simultaneously, and the ADS compound confers better efficacy than either the antibody or the drug alone due to a synergism of the ADS compound.
(FR) L'invention concerne un procédé de production synergique et une efficacité améliorée dans le traitement d'une maladie chez un sujet, comprenant l'utilisation d'un anticorps, l'anticorps étant un anticorps classique ou une molécule biologique modifiée qui bloque une première cible chez le sujet ; l'utilisation d'un médicament, le médicament étant un agent à petite molécule qui bloque la première cible ou une deuxième cible chez le sujet ; la connexion de l'anticorps et du médicament au moyen d'un lieur en vue de former un composé de synergie anticorps-médicament (ADS) ; et le traitement de la maladie au moyen du composé ADS. Le lieur est hydrolysé chez le sujet pendant un certain temps de sorte que l'anticorps et le médicament assurent leurs fonctions simultanément, et le composé ADS confère une meilleure efficacité que l'anticorps ou que le médicament seul en raison d'une synergie du composé ADS.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CA3010623AU2017214475KR1020180105235CN108602879EP3411399BR112018014467
US20190030179